WO2015150944A1 - Composition pharmaceutiques orales solides comprenant du cinacalcet ou l'un des sels de celui-ci - Google Patents

Composition pharmaceutiques orales solides comprenant du cinacalcet ou l'un des sels de celui-ci Download PDF

Info

Publication number
WO2015150944A1
WO2015150944A1 PCT/IB2015/051900 IB2015051900W WO2015150944A1 WO 2015150944 A1 WO2015150944 A1 WO 2015150944A1 IB 2015051900 W IB2015051900 W IB 2015051900W WO 2015150944 A1 WO2015150944 A1 WO 2015150944A1
Authority
WO
WIPO (PCT)
Prior art keywords
cinacalcet
solid oral
oral pharmaceutical
composition
pharmaceutical composition
Prior art date
Application number
PCT/IB2015/051900
Other languages
English (en)
Inventor
Amar AGARWAL
Saurabh Gupta
Venkataramana NAIDU
Girish Kumar Jain
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Publication of WO2015150944A1 publication Critical patent/WO2015150944A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to solid oral pharmaceutical compositions of cinacalcet or a salt thereof.
  • cinacalcet composition with desired release profile and excellent storage stability can be prepared.
  • process of preparing solid oral pharmaceutical compositions of cinacalcet or a salt thereof There is also provided a method of treating secondary hyperparathyroidism and hypercalcemia in patients in need thereof by using the composition of cinacalcet or a salt thereof.
  • the invention also includes process for preparing solid oral pharmaceutical compositions of cinacalcet or a salt thereof
  • Calcium receptor-active compounds are small organic molecules that act as allosteric activators of calcium sensing receptors. At the parathyroid cell, they lower the threshold of receptor activation by extracellular calcium ions and diminish parathyroid hormone secretion. Cinacalcet is one of the first calcimimetic agents in its class to have reached the marketplace successfully.
  • Cinacalcet is marketed as a tablet dosage form under the brand name Sensipar ® in US and Mimpara ® in Europe and both products contains the hydrochloride salt of cinacalcet. Cinacalcet tablets are available in strengths of 30 mg, 60 mg, and 90 mg of cinacalcet as the free base equivalent (33 mg, 66 mg, and 99 mg as the hydrochloride salt, respectively). It is used for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for hypercalcemia in patients with parathyroid carcinoma and for severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy.
  • HPT secondary hyperparathyroidism
  • CKD chronic kidney disease
  • the hydrochloride salt of cinacalcet is a white to off-white, crystalline solid that is soluble in methanol or 95% ethanol and slightly soluble in water. Cinacalcet is described chemically as N-[1 -(R)-(-)-(1 -naphthyl) ethyl]-3-[3(trifluoromethyl) phenyl]- " ! -aminopropane hydrochloride and has the following structural formula:
  • PCT Application Publication No. WO 2008064202 discloses modified-release pharmaceutical formulations comprising cinacalcet.
  • U.S. Patent Application No. 20080181959 discloses the solid composites of cinacalcet and processes for preparing the solid composites having immediate and controlled-release.
  • PCT Application No. WO 2013107503 discloses a novel method for producing pharmaceutical compositions of cinacalcet or pharmaceutically acceptable salt thereof in substantially dry powder form, which is suitable for direct compression and for providing improved features of dissolution and compressibility.
  • U.S. Patent No. 7,829,595 discloses a pharmaceutical composition comprising cinacalcet and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile.
  • Inventors have provided an improved composition of cinacalcet or a salt thereof by reducing the excipient load, as it is always desirable to reduce the excess load of excipient from the composition provided its release profile and stability remains unaltered.
  • compositions devoid of disintegrating agent that exhibits desired release profile, and more particularly exhibit a similar dissolution profile compared to currently marketed cinacalcet tablets containing disintegrating agents.
  • Such composition may remain stable during the period intended for use.
  • a solid oral pharmaceutical composition comprising:
  • composition is devoid of any disintegrating agent.
  • a tablet comprising:
  • the tablet is devoid of any disintegrating agent.
  • a tablet comprising:
  • the tablet is devoid of any disintegrating agent.
  • a tablet comprising:
  • the tablet is devoid of any disintegrating agent.
  • a solid oral pharmaceutical composition comprising:
  • composition (e) a coating comprising one or more layers of hydroxypropyl methyl cellulose; wherein the composition is devoid of any disintegrating agent.
  • a solid oral pharmaceutical composition comprising: (a) about 5 to 50% w/w of cinacalcet or a salt thereof;
  • composition (e) a coating comprising about 0.5 to 4% w/w hydroxypropyl methylcellulose; wherein the composition is devoid of any disintegrating agent.
  • a solid oral pharmaceutical composition comprising:
  • composition is devoid of any disintegrating agent.
  • a solid oral pharmaceutical composition of cinacalcet or a salt thereof wherein the ratio of the amount of cinacalcet to diluents in the composition ranges from about 1 :0.1 to about 1 :1 .
  • the diluents may be present either partly intra and partly extragranular or fully in either intragranular or extragranular part of the composition.
  • a solid oral pharmaceutical composition of cinacalcet or a salt thereof wherein the ratio of the amount of cinacalcet to binder in the composition ranges from about 1 :1 to about 1 :10.
  • One or more pharmaceutically acceptable excipients that may be present in the cinacalcet composition comprises at least one diluent, at least one binder, and at least one lubricant, and optionally at least one film forming polymer in the form of a coating.
  • the amount of diluent may vary within a range of from about 50 to 90% w/w, preferably 60 to 80% w/w by total weight of the composition.
  • the amount of binder may vary within a range of from about 1 to 30% w/w, preferably 1 to 20% w/w, in particular 1 to 10% w/w by weight based on the total weight of the composition.
  • the amount of lubricant may vary within a range of from about 0.1 to 5% w/w, e.g. 0.5 to 2% w/w by weight based on the total weight of the composition.
  • the amount of coating may vary from about 1 to 5% w/w, preferably from 1 .5 to 2.5% w/w by weight based on the total weight of the composition.
  • a tablet comprising cinacalcet or a salt thereof, one or more diluents in a total amount of about 50 to 90% w/w, one or more binders in a total amount of about 1 to 20% w/w, and one or more lubricants in a total amount of about 0.5 to 2% w/w by weight based on the total weight of the tablet; wherein the tablet is devoid of any disintegrating agent.
  • the composition releases more than 85% and preferably more than 90% by weight of the initial amount of cinacalcet within 30 minutes when measured using USP type II dissolution apparatus in 900 ml of 0.05N hydrochloric acid at a temperature of about 37°C and at a rotation speed of about 75 rpm.
  • a solid oral pharmaceutical composition which retains at least 90% by weight of the total content of cinacalcet or a salt thereof after storing at 40°C and 75% relative humidity over a period of at least 3 months.
  • a process of preparing a solid oral pharmaceutical composition of cinacalcet or a salt thereof which process comprises steps of:
  • step (b) optionally lubricating the granules obtained in step (a) to form a lubricated blend
  • step (c) compressing the granules obtained in step (a) or the lubricated blend obtained in step (b) to form a core comprising cinacalcet or a salt thereof, and
  • step (d) optionally coating the core obtained in step (c) with a composition comprising one or more film forming polymers.
  • step (b) compressing the granules obtained in step (a) to form a tablet
  • each excipient and the amounts relative to other excipients are similarly dependent on the desired properties of the tablet and may also be chosen by routine experimentation.
  • the tablet may be chosen to exhibit accelerated and/or delayed release of cinacalcet with or without quantitative control of the release of cinacalcet.
  • the tablet is chosen to exhibit immediate release of the cinacalcet.
  • compositions such as tablets, comprising cinacalcet which do not contain any disintegrating agent may be obtained.
  • inventors of the present invention have formulated a solid oral pharmaceutical composition devoid of disintegrating agent that can exhibit desired release profile or a similar dissolution profile compared to the currently marketed cinacalcet tablets containing disintegrating agents.
  • cinacalcet used throughout the specification refers to not only cinacalcet per se, but also its other pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof. Particularly, preferred form of cinacalcet is cinacalcet base.
  • Suitable filler/diluent includes, but are not limited to calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethylcellulose, dextrin, dextrose, fructose, lactitol, lactose (e.g.
  • Suitable binders include, but not limited to microcrystalline cellulose, hydroxymethyl cellulose, gelatin, sugars (including sucrose, glucose, dextrose, lactose, and sorbitol), waxes, polyethylene glycol, natural and synthetic gums (e.g. acacia, tragacanth, sodium alginate, celluloses, and Veegum), and synthetic polymers such as polymethacrylates, polyvinylpyrrolidone, ethylcellulose, hydroxyethyl cellulose, polyethylene oxide, mixtures thereof and the like.
  • Suitable lubricants include, but not limited to sodium oleate, sodium stearate, sodium benzoate, sodium stearate, sodium chloride, stearic acid, sodium stearyl fumarate, calcium stearate, magnesium stearate, magnesium lauryl sulfate, sodium stearyl fumarate, sucrose esters or fatty acid, polyethylene glycol, talc, mixtures thereof and the like.
  • compositions of the present invention are devoid of such disintegrants.
  • the solid oral pharmaceutical composition comprises:
  • composition is devoid of any disintegrating agent.
  • the solid oral pharmaceutical composition comprises: (a) cinacalcet or a salt thereof; (b) one or more pharmaceutically acceptable excipients selected from the category of diluent, binder, and lubricant, and
  • composition is devoid of any disintegrating agent.
  • the solid oral pharmaceutical composition of the present invention may be prepared in the form of a tablet, a capsule, a mini-tablet, granules, pellets and a caplet. Particularly preferred for is a tablet.
  • the solid oral composition of the present invention may be prepared by various methods known to the person skilled in the art, including wet granulation, dry granulation, direct compression and slugging. Particularly preferred method includes wet-granulation followed by compression.
  • a solid bulk of granulate mass which is necessary for manufacturing tablets, can be manufactured using two main processes, wet granulation or dry granulation. Tablets may also be manufactured using direct compression. Direct compression relates to the tableting process itself rather than preparation of the starting material.
  • wet granulation components are typically mixed and granulated using a wet binder. The wet granulates are then sieved, dried and optionally ground prior to compressing into tablets. Wet granulation is used extensively in the pharmaceutical industry although it has proven to be a difficult method, mainly because the liquids needed in the granule and tablet manufacturing processes often have an adverse effect on the characteristics of the active pharmaceutical ingredients (APIs) and/or on the end product such as a tablet.
  • APIs active pharmaceutical ingredients
  • Dry granulation is usually described as a method of controlled crushing of precompacted powders densified by either slugging or passing the material between two counter-rotating rolls. More specifically, powdered components that may contain very fine particles are typically mixed prior to being compacted to yield hard slugs which are then ground and sieved before the addition of other ingredients and final compression to form tablets. Because substantially no liquids are used in the dry granulation process, the issues related to wet granulation are avoided. Although dry granulation would in many cases appear to be the best way to produce products such as tablets containing APIs, it has been relatively little used because of the challenges in producing the desired kind of granules as well as managing the granulated material in the manufacturing process.
  • Direct compression is generally considered to be the simplest and the most economical process for producing tablets. However, it may only be applied to materials that do not need to be granulated before tableting. Direct compression requires only two principal steps; i.e., the mixing of all the ingredients and the compression of this mixture. However, direct compression is applicable to only a relatively small number of substances as the ingredients of the tablets often need to be processed by some granulation technique to make them compressible and/or for improving their homogeneity and flow-ability.
  • the process of preparing a solid oral pharmaceutical composition of cinacalcet or a salt thereof comprises steps of:
  • step (b) optionally lubricating the granules obtained in step (a) to form a lubricated blend;
  • step (c) compressing the granules obtained in step (a) or the lubricated blend obtained in step (b) to form a core comprising cinacalcet or a salt thereof, and
  • step (d) optionally coating the core obtained in step (c) with a composition comprising one or more film forming polymers.
  • the process of preparing tablet of cinacalcet or a salt thereof comprises steps of:
  • step (b) compressing the granules obtained in step (a) to form a tablet
  • ratio of the amount of cinacalcet to diluents in the composition ranges from about 1 :0.1 to about 1 :1 . In a further embodiment, ratio of the amount of cinacalcet to binder in the composition ranges from about 1 :1 to about 1 :10.
  • the solid oral pharmaceutical composition comprises:
  • composition is devoid of any disintegrating agent.
  • the solid oral pharmaceutical composition comprises: (a) about 5 to 50% w/w of cinacalcet or a salt thereof; (b) about 10 to 60% w/w of microcrystalline cellulose;
  • composition (e) a coating comprising about 0.5 to 4% w/w hydroxypropyl methylcellulose; wherein the composition is devoid of any disintegrating agent.
  • cinacalcet tablet comprises one or more diluents in a total amount of about 50 to 90% w/w, one or more binders in a total amount of about 1 to 20% w/w, and one or more lubricants in a total amount of about 0.5 to 2% w/w by weight based on the total weight of the tablet
  • the solid oral pharmaceutical composition comprises:
  • composition is devoid of any disintegrating agent.
  • the solid oral pharmaceutical composition comprising cinacalcet or a salt thereof of in accordance with the present invention can be administered for treating secondary hyperparathyroidism and hypercalcemia to patients in need thereof.
  • Microcrystalline cellulose and 50% quantity of polyvinylpyrrolidone were sifted through # 30 sieve and dry mixed.
  • the dry blend was granulated using dispersion of cinacalcet and remaining quantity of polyvinylpyrrolidone in purified water, to form wet mass.
  • Thus formed wet mass was dried in fluidized bed dryer at 60°C till LOD of less than 2% is achieved.
  • Granules were sized through # 20 sieve. Dried and sized granules were mixed for 15 min with extragranular material lactose and lubricated with magnesium stearate in a blender. This lubricated blend was compressed using suitable tooling on compression machine to form tablets. The compressed tablets were coated using opadry green dispersion in water using coating pan.

Abstract

La présente invention concerne des compositions pharmaceutiques orales solides comprenant du cinacalcet ou l'un des sels de celui-ci. En particulier, la présente invention concerne des compositions pharmaceutiques orales solides comprenant de cinacalcet ou l'un des sels de celui-ci et au moins un excipient pharmaceutiquement acceptable autre qu'un agent délitant. En outre, la présente invention concerne un procédé de préparation de compositions pharmaceutiques orales solides de cinacalcet ou d'un sel de celui-ci. La présente invention concerne en outre un procédé de traitement de l'hyperparathyroïdisme secondaire et de l'hypercalcémie chez des patients ayant besoin de celui-ci par utilisation de telles compositions.
PCT/IB2015/051900 2014-03-29 2015-03-16 Composition pharmaceutiques orales solides comprenant du cinacalcet ou l'un des sels de celui-ci WO2015150944A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1183/MUM/2014 2014-03-29
IN1182MU2014 2014-03-29
IN1183MU2014 2014-03-29
IN1182/MUM/2014 2014-03-29

Publications (1)

Publication Number Publication Date
WO2015150944A1 true WO2015150944A1 (fr) 2015-10-08

Family

ID=54239465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/051900 WO2015150944A1 (fr) 2014-03-29 2015-03-16 Composition pharmaceutiques orales solides comprenant du cinacalcet ou l'un des sels de celui-ci

Country Status (1)

Country Link
WO (1) WO2015150944A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019186516A1 (fr) 2018-03-30 2019-10-03 Ftf Pharma Private Limited Formes posologiques liquides de cinacalcet ou d'un sel de celui-ci

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064202A2 (fr) 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
US20080181959A1 (en) 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
WO2010034497A2 (fr) * 2008-09-25 2010-04-01 Ratiopharm Gmbh Cinacalcet compacté
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
US20110287065A1 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet compositions
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
WO2013107503A1 (fr) 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Procédé de préparation de compositions de cinacalcet destinées à la fabrication directe de comprimés
WO2014207691A1 (fr) * 2013-06-26 2014-12-31 Jubilant Life Sciences Limited Composition de cinacalcet sans désintégrant

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
US20080181959A1 (en) 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
WO2008064202A2 (fr) 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
WO2010034497A2 (fr) * 2008-09-25 2010-04-01 Ratiopharm Gmbh Cinacalcet compacté
US20110287065A1 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet compositions
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
WO2013107503A1 (fr) 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Procédé de préparation de compositions de cinacalcet destinées à la fabrication directe de comprimés
WO2014207691A1 (fr) * 2013-06-26 2014-12-31 Jubilant Life Sciences Limited Composition de cinacalcet sans désintégrant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETER KLEINEBUDDE: "Roll compaction / dry granulation: pharmaceutical applications", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 58, 2004, pages 317 - 326

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019186516A1 (fr) 2018-03-30 2019-10-03 Ftf Pharma Private Limited Formes posologiques liquides de cinacalcet ou d'un sel de celui-ci

Similar Documents

Publication Publication Date Title
EP2136793B1 (fr) Formulations pour comprimés contenant des sels de 8-[{1-(3,5-bis- (trifluorométhyl)phényl)-éthoxy}-méthyl]-8-phényl-1,7-diaza-spiro[4,5]- décan-2-one et comprimés
WO2016028689A1 (fr) Comprimés de rucaparib à dosage élevé
JP2009102409A (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
WO2014101986A1 (fr) Procédé de granulation à sec pour la production de compositions de comprimés de metformine et compositions associées
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
WO2015110952A1 (fr) Compositions pharmaceutiques orales solides comprenant du ticagrelor ou un sel de ce dernier
JP2012503613A (ja) コンパクト化シナカルセット
US11000523B2 (en) Ceritinib formulation
EP2804588B1 (fr) Procédé de préparation de compositions de cinacalcet destinées à la fabrication directe de comprimés
WO2013082706A1 (fr) Formulation de doxylamine et de pyridoxine à libération prolongée sans délitant et procédé de fabrication associé
WO2012136839A1 (fr) Formulation sèche et composition pharmaceutique comprenant une fésotérodine ou un sel ou un solvate de celle-ci
EP2295040A1 (fr) Compositions pharmaceutiques de pramipexole
EP3860606A1 (fr) Composition pharmaceutique comprenant de l'ésylate ou du tosylate de lenvatinib
CA3104695A1 (fr) Formules d'ag10
WO2015150944A1 (fr) Composition pharmaceutiques orales solides comprenant du cinacalcet ou l'un des sels de celui-ci
WO2019012552A1 (fr) Compositions de composés organiques ferriques
JP5680607B2 (ja) 安定固形製剤及びその製造法
JP6199922B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
Pimple et al. Formulation and evaluation of immediate release tablets of s (-) metoprolol succinate using roller compaction approach
JP6233911B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
KR102002906B1 (ko) 셀레콕시브를 포함하는 정제
CA2954393C (fr) Formes pharmaceutiques
JP2023143873A (ja) ミラベグロン含有徐放性錠剤及びその製造方法、並びにミラベグロン含有徐放性錠剤の変色・膨張抑制方法
JP2018009032A (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
EA041427B1 (ru) Фармацевтические лекарственные формы

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15717232

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase
122 Ep: pct application non-entry in european phase

Ref document number: 15717232

Country of ref document: EP

Kind code of ref document: A1